Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulfoxone is a water-soluble sulfone and synthetic sulfonamide antibiotic primarily used as an antileprosy drug. It has also been used with limited success in the treatment of dermatitis herpetiformis and was at times considered for pulmonary tuberculosis. Sulfoxone acts as a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase, blocking the binding of para-aminobenzoic acid (PABA) and thereby inhibiting folic acid synthesis essential for bacterial growth. This mechanism renders it bacteriostatic against most gram-positive and many gram-negative organisms. The drug is rapidly absorbed orally, widely distributed in tissues, metabolized hepatically, and has an elimination half-life of 3–8 hours. Its use under the brand name Diasone has been discontinued.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulfoxone.